181 related articles for article (PubMed ID: 38473786)
21. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
[TBL] [Abstract][Full Text] [Related]
22. Integration analysis identifies MYBL1 as a novel immunotherapy biomarker affecting the immune microenvironment in clear cell renal cell carcinoma: Evidence based on machine learning and experiments.
Wang T; Jian W; Xue W; Meng Y; Xia Z; Li Q; Xu S; Dong Y; Mao A; Zhang C
Front Immunol; 2022; 13():1080403. PubMed ID: 36591240
[TBL] [Abstract][Full Text] [Related]
23. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L
Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of 1p36 locus deletion in adenoid cystic carcinoma of the salivary glands.
Šteiner P; Andreasen S; Grossmann P; Hauer L; Vaněček T; Miesbauerová M; Santana T; Kiss K; Slouka D; Skálová A
Virchows Arch; 2018 Oct; 473(4):471-480. PubMed ID: 29619555
[TBL] [Abstract][Full Text] [Related]
25.
Guo H; Zhang B; Nairn AV; Nagy T; Moremen KW; Buckhaults P; Pierce M
J Biol Chem; 2017 Mar; 292(10):4123-4137. PubMed ID: 28096468
[TBL] [Abstract][Full Text] [Related]
26. MYC and DNMT3A-mediated DNA methylation represses microRNA-200b in triple negative breast cancer.
Pang Y; Liu J; Li X; Xiao G; Wang H; Yang G; Li Y; Tang SC; Qin S; Du N; Zhang H; Liu D; Sun X; Ren H
J Cell Mol Med; 2018 Dec; 22(12):6262-6274. PubMed ID: 30324719
[TBL] [Abstract][Full Text] [Related]
27. The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling.
Chen B; Dragomir MP; Fabris L; Bayraktar R; Knutsen E; Liu X; Tang C; Li Y; Shimura T; Ivkovic TC; De Los Santos MC; Anfossi S; Shimizu M; Shah MY; Ling H; Shen P; Multani AS; Pardini B; Burks JK; Katayama H; Reineke LC; Huo L; Syed M; Song S; Ferracin M; Oki E; Fromm B; Ivan C; Bhuvaneshwar K; Gusev Y; Mimori K; Menter D; Sen S; Matsuyama T; Uetake H; Vasilescu C; Kopetz S; Parker-Thornburg J; Taguchi A; Hanash SM; Girnita L; Slaby O; Goel A; Varani G; Gagea M; Li C; Ajani JA; Calin GA
Gastroenterology; 2020 Dec; 159(6):2146-2162.e33. PubMed ID: 32805281
[TBL] [Abstract][Full Text] [Related]
28. Identification of candidate genes associated with triple negative breast cancer.
Player A; Abraham N; Burrell K; Bengone IO; Harris A; Nunez L; Willaims T; Kwende S; Walls W
Genes Cancer; 2017 Jul; 8(7-8):659-672. PubMed ID: 28966727
[TBL] [Abstract][Full Text] [Related]
29. Gene Expression Alterations Associated with Oleuropein-Induced Antiproliferative Effects and S-Phase Cell Cycle Arrest in Triple-Negative Breast Cancer Cells.
Messeha SS; Zarmouh NO; Asiri A; Soliman KFA
Nutrients; 2020 Dec; 12(12):. PubMed ID: 33297339
[TBL] [Abstract][Full Text] [Related]
30. [Low grade glioma with MYBL1 alteration: Case report of an uncommon pediatric neoplasm].
Appay R; Tauziède-Espariat A; Silva K; Fritih R; Scavarda D; Delteil C; Varlet P; Figarella-Branger D
Ann Pathol; 2021 Feb; 41(1):129-133. PubMed ID: 32732147
[TBL] [Abstract][Full Text] [Related]
31. QM-FISH analysis of the genes involved in the G1/S checkpoint signaling pathway in triple-negative breast cancer.
Zhang S; Shao Y; Hou G; Bai J; Yuan W; Hu L; Cheng T; Zetterberg A; Zhang J
Tumour Biol; 2014 Mar; 35(3):1847-54. PubMed ID: 24096545
[TBL] [Abstract][Full Text] [Related]
32. CircCD44 plays oncogenic roles in triple-negative breast cancer by modulating the miR-502-5p/KRAS and IGF2BP2/Myc axes.
Li J; Gao X; Zhang Z; Lai Y; Lin X; Lin B; Ma M; Liang X; Li X; Lv W; Lin Y; Zhang N
Mol Cancer; 2021 Oct; 20(1):138. PubMed ID: 34696797
[TBL] [Abstract][Full Text] [Related]
33. BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathways.
Zhang Y; Xu B; Shi J; Li J; Lu X; Xu L; Yang H; Hamad N; Wang C; Napier D; He S; Liu C; Liu Z; Qian H; Chen L; Wei X; Zheng X; Huang JA; Thibault O; Craven R; Wei D; Pan Y; Zhou BP; Wu Y; Yang XH
Cell Oncol (Dordr); 2020 Dec; 43(6):1049-1066. PubMed ID: 33006750
[TBL] [Abstract][Full Text] [Related]
34. The long noncoding RNA sONE represses triple-negative breast cancer aggressiveness through inducing the expression of miR-34a, miR-15a, miR-16, and let-7a.
Youness RA; Hafez HM; Khallaf E; Assal RA; Abdel Motaal A; Gad MZ
J Cell Physiol; 2019 Nov; 234(11):20286-20297. PubMed ID: 30968427
[TBL] [Abstract][Full Text] [Related]
35. Copy number variation in triple negative breast cancer samples associated with lymph node metastasis.
Pariyar M; Johns A; Thorne RF; Scott RJ; Avery-Kiejda KA
Neoplasia; 2021 Aug; 23(8):743-753. PubMed ID: 34225099
[TBL] [Abstract][Full Text] [Related]
36. TOP1 inhibition induces bifurcated JNK/MYC signaling that dictates cancer cell sensitivity.
Liu Q; Chung S; Murata MM; Han B; Gao B; Zhang M; Lee TY; Chirshev E; Unternaehrer J; Tanaka H; Giuliano AE; Cui Y; Cui X
Int J Biol Sci; 2022; 18(10):4203-4218. PubMed ID: 35844787
[No Abstract] [Full Text] [Related]
37. PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.
Brasó-Maristany F; Filosto S; Catchpole S; Marlow R; Quist J; Francesch-Domenech E; Plumb DA; Zakka L; Gazinska P; Liccardi G; Meier P; Gris-Oliver A; Cheang MC; Perdrix-Rosell A; Shafat M; Noël E; Patel N; McEachern K; Scaltriti M; Castel P; Noor F; Buus R; Mathew S; Watkins J; Serra V; Marra P; Grigoriadis A; Tutt AN
Nat Med; 2016 Nov; 22(11):1303-1313. PubMed ID: 27775704
[TBL] [Abstract][Full Text] [Related]
38. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.
Wang DY; Gendoo DMA; Ben-David Y; Woodgett JR; Zacksenhaus E
Breast Cancer Res; 2019 Jan; 21(1):18. PubMed ID: 30704524
[TBL] [Abstract][Full Text] [Related]
39. The Landscape of MYB/MYBL1- and Peri-MYB/MYBL1-Associated Rearrangements in Adenoid Cystic Carcinoma.
Ueda K; Murase T; Kawakita D; Nagao T; Kusafuka K; Nakaguro M; Urano M; Yamamoto H; Taguchi KI; Kano S; Tada Y; Tsukahara K; Okami K; Onitsuka T; Fujimoto Y; Sakurai K; Hanai N; Nagao T; Kawata R; Hato N; Nibu KI; Inagaki H
Mod Pathol; 2023 Oct; 36(10):100274. PubMed ID: 37423587
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.
Camarda R; Zhou AY; Kohnz RA; Balakrishnan S; Mahieu C; Anderton B; Eyob H; Kajimura S; Tward A; Krings G; Nomura DK; Goga A
Nat Med; 2016 Apr; 22(4):427-32. PubMed ID: 26950360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
